Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
PZ HTL SA
GLOBETECH PUBLISHING

Breast and Ovarian Cancer Gene Patents Invalidated by US Supreme Court

By BiotechDaily International staff writers
Posted on 26 Jun 2013
On June 13, 2013, the US Supreme Court (Washington DC, USA) unanimously invalidated patents on two genes tied to ovarian and hereditary breast cancer in response to a lawsuit filed by the American Civil Liberties Union (ACLU; New York, NY, USA) and the Public Patent Foundation (PUBPAT; New York, NY, USA) on behalf of genetic counselors, patients, researchers, breast cancer and women’s health groups, and medical professional associations representing 150,000 geneticists, pathologists, and laboratory specialists.

The patents allowed Myriad Genetics (Salt Lake City, UT, USA) to control access to the genes, known as breast cancer1 (BRCA1) and BRCA2, thus giving them the right to restrict others from doing diagnostic or research testing of the genes, which can be crucial for individuals making important medical decisions. The patents also allowed Myriad to set the terms and cost of testing and made it hard for women to gain access to alternate testing or acquire a comprehensive second opinion about their test findings.

“Today, the court struck down a major barrier to patient care and medical innovation,” said Sandra Park, senior staff attorney with the ACLU Women’s Rights Project. “Myriad did not invent the BRCA genes and should not control them. Because of this ruling, patients will have greater access to genetic testing and scientists can engage in research on these genes without fear of being sued.”

The court found that the patents on human genes are invalid, which represents a vital shift in patent law and overturns current Patent Office policy. The court also found that patents on complementary DNA (cDNA), are patent-eligible. Scientists can provide genetic testing without relying on cDNA. Thus, the court’s ruling lifted the patent hurdle to offering genetic diagnostic testing.

“The court rightfully found that patents cannot be awarded for something so fundamental to nature as DNA,” said Daniel B. Ravicher, executive director of PUBPAT and co-counsel in the lawsuit.

A US federal district court invalidated all of the challenged patents in 2010. In 2012, for the second time, a US federal appeals court ruled that the patents on the genes were lawful. Its 2-1 decision followed a Supreme Court order directing the appeals court to reconsider its initial decision in light of a related patent case decided by the Supreme Court the spring of 2012.

Related Links:

American Civil Liberties Union
Public Patent Foundation
Myriad Genetics



Channels

Genomics/Proteomics

view channel
Image: The TheraCyte cell encapsulation device (Photo courtesy of TheraCyte, Inc.).

Encapsulated Human-Insulin-Producing Progenitor Cells Cure Diabetes in Mouse Model

A breakthrough system that allows subcutaneous implantation of encapsulated immature pancreatic cells (beta progenitor cells) was shown to produce enough insulin to correct the symptoms of diabetes in a mouse model.... Read more

Drug Discovery

view channel
Image: Chitosan is derived from the shells of shrimp and other sea crustaceans, including Alaskan pink shrimp, pictured here (Photo courtesy of NOAA - [US] National Oceanic and Atmospheric Administration).

Chitosan Treatment Clears the Way for Antibiotics to Eliminate Recurrent Urinary Tract Infections

Recurrent urinary tract infection was successfully resolved in a mouse model by treatment with the exfoliant chitosan followed by a round of antibiotics. Bacterial urinary tract infection (UTI), most... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.